Lipella Pharmaceuticals Enters Manufacturing Collaboration with Cook MyoSite

Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has entered a manufacturing collaboration with Cook MyoSite for its lead drug candidate, LP-10.

In March 2023, the company successfully completed a Phase 2a clinical trial evaluating LP-10 as a potential therapeutic for hemorrhagic cystitis, a rare and debilitating disease with no approved treatment.


Lipella’s collaboration with Cook MyoSite will facilitate Chemistry, Manufacturing, and Control (“CMC”) documentation for LP-10 (liposomal tacrolimus). Cook MyoSite has 19 years of GMP manufacturing expertise.

Lipella states that the collaboration will expedite its efforts to produce clinical supplies and research products for LP-10, and will play a crucial role in advancing the commercial approval of LP-10.

The company has entered the agreement in anticipation of its forthcoming Investigational New Drug (IND) application.

LP-10 has been granted Orphan Drug Designation by the FDA.

About Lipella Pharmaceuticals

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit or LinkedIn.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Pharmaceuticals Enters Manufacturing Collaboration with Cook MyoSite

Editor Prism MarketView